Skip to main content

Maria del Mar Riveiro Barciela

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Maria del Mar Riveiro Barciela

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Análisis de la interacción de los virus de la hepatitis B y D con el receptor del hepatocito y estudio prospectivo de la complejidad de sus quasiespecies virales

IP: Maria Buti Ferret
Collaborators: Lluís Viladomiu Catà, Maria del Mar Riveiro Barciela, Carolina Gonzalez Fernandez, David Tabernero Caellas
Funding agency: Instituto de Salud Carlos III
Funding: 147015
Reference: PI14/01416
Duration: 01/01/2015 - 31/12/2017

Estudio alegorizado de dos estrategias de tratamiento con Ribavirina para la Hepatitis Crónica E y formas agudas graves.

IP: -
Collaborators: Maria del Mar Riveiro Barciela, Josep Quer Sivila, Basilio Rodriguez Diez, Cristina Berastegui Garcia, Virginia Robles Alonso
Funding agency: Instituto de Salud Carlos III
Funding: 261360
Reference: ICI14/00367
Duration: 01/01/2015 - 30/06/2019

Malalties Hepatobiliars (GRC)

IP: -
Collaborators: Beatriz Minguez Rosique, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Antonio González Fernández, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Silvia Sauleda Oliveras, Maria Buti Ferret, Josep Quer Sivila, Josep Gregori Font, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Juan Ignacio Esteban Mur, Meritxell Ventura Cots, Macarena Simon-Talero Horga, Joan Genescà Ferrer, David Tabernero Caellas
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 65000
Reference: 2014 SGR 421
Duration: 01/01/2014 - 31/12/2016

Análisis de situación y estrategia de manejo de pacientes con infección crónica por VHB sin criterios de tratamiento según las guías de la Asociación Europea para el estudio del hígado

IP: Maria Buti Ferret
Collaborators: Maria del Mar Riveiro Barciela
Funding agency: GILEAD SCIENCES SLU
Funding: 39591
Reference: GLD13/00137
Duration: 18/09/2013 - 17/09/2014

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

Related professionals

Jose Fernando Rodríguez Palomares

Jose Fernando Rodríguez Palomares

Main researcher
Cardiovascular Diseases
Read more
Muñoz Vaño, Vicent

Muñoz Vaño, Vicent

Research technician
Nephrology and kidney transplantation
Read more
Català Santarrufina, Alba

Català Santarrufina, Alba

Research technician
Cardiovascular Diseases
Read more
Maria Angeles Jiménez Fuentes

Maria Angeles Jiménez Fuentes

Pneumology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.